Squarepoint’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding TVTX
Squarepoint's TVTX Position: Q3 2026 in Review
Squarepoint increased its Travere Therapeutics (TVTX) stake by 209% in Q3 2026, buying an estimated $14M and bringing the position to 339,833 shares worth $20M. The position accounts for 0.02% of the portfolio, ranked #684.
Squarepoint first reported a position in TVTX in Q4 2015 and has held it in 34 quarters since. 317 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.
- Squarepoint held 339,833 shares of Travere Therapeutics worth $20M as of Q3 2026.
- Squarepoint bought 230,026 Travere Therapeutics shares in Q3 2026, an estimated $14M.
- Travere Therapeutics made up 0.02% of Squarepoint's portfolio in Q3 2026, its #684 holding.
- Squarepoint first reported a position in Travere Therapeutics in Q4 2015 and has held it in 34 quarters since.
- 317 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.
Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.